Recommended Conferences

Human Genetics and Genetic Disorders

Miami, USA

Tissue Engineering and Regenerative Medicine

Chicago, USA
Related Subjects
 

CAF-1 is essential for heterochromatin organization in pluripotent embryonic cells

Author(s): Houlard M, Berlivet S, Probst AV, Quivy JP, Héry P, et al.

Abstract

During mammalian development, chromatin dynamics and epigenetic marking are important for genome reprogramming. Recent data suggest an important role for the chromatin assembly machinery in this process. To analyze the role of chromatin assembly factor 1 (CAF-1) during pre-implantation development, we generated a mouse line carrying a targeted mutation in the gene encoding its large subunit, p150CAF-1. Loss of p150CAF-1 in homozygous mutants leads to developmental arrest at the 16-cell stage. Absence of p150CAF-1 in these embryos results in severe alterations in the nuclear organization of constitutive heterochromatin. We provide evidence that in wild-type embryos, heterochromatin domains are extensively reorganized between the two-cell and blastocyst stages. In p150CAF-1 mutant 16-cell stage embryos, the altered organization of heterochromatin displays similarities to the structure of heterochromatin in two- to four-cell stage wild-type embryos, suggesting that CAF-1 is required for the maturation of heterochromatin during preimplantation development. In embryonic stem cells, depletion of p150CAF-1 using RNA interference results in the mislocalization, loss of clustering, and decondensation of pericentric heterochromatin domains. Furthermore, loss of CAF-1 in these cells results in the alteration of epigenetic histone methylation marks at the level of pericentric heterochromatin. These alterations of heterochromatin are not found in p150CAF-1-depleted mouse embryonic fibroblasts, which are cells that are already lineage committed, suggesting that CAF-1 is specifically required for heterochromatin organization in pluripotent embryonic cells. Our findings underline the role of the chromatin assembly machinery in controlling the spatial organization and epigenetic marking of the genome in early embryos and embryonic stem cells.

Similar Articles

Naive and primed pluripotent states

Author(s): Nichols J, Smith A

MicroRNAs: key regulators of stem cells

Author(s): Gangaraju VK, Lin H

Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse

Author(s): Stadtfeld M, Maherali N, Breault DT, Hochedlinger K

Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells

Author(s): Chan EM, Ratanasirintrawoot S, Park IH, Manos PD, Loh YH, et al.

Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution

Author(s): Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, et al.

Epigenetic memory in induced pluripotent stem cells

Author(s): Kim K, Doi A, Wen B, Ng K, Zhao R, et al.

Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells

Author(s): Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, et al.

Immunogenicity of induced pluripotent stem cells

Author(s): Zhao T, Zhang ZN, Rong Z, Xu Y

Nuclear transfer to eggs and oocytes

Author(s): Gurdon JB, Wilmut I

Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein

Author(s): Pivot-Pajot C, Caron C, Govin J, Vion A, Rousseaux S, et al.

Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors

Author(s): Jude CD, Climer L, Xu D, Artinger E, Fisher JK, et al.

Histone H4-K16 acetylation controls chromatin structure and protein interactions

Author(s): Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, et al.

Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs

Author(s): Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, et al.

Patient-specific induced pluripotent stem-cell models for long-QT syndrome

Author(s): Moretti A, Bellin M, Welling A, Jung CB, Lam JT, et al.

Modelling the long QT syndrome with induced pluripotent stem cells

Author(s): Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, et al.